Schedule 13G/A: Eventide, Kuruvilla & John Report 2.0% of CLDX

Rhea-AI Filing Summary

This Schedule 13G/A reports that Eventide Asset Management, LLC and two individuals, Finny Kuruvilla, M.D., Ph.D. and Robin C. John, each are associated with an aggregate beneficial ownership of 1,356,186 shares of Celldex Therapeutics common stock, representing 2.0% of the class. The filing cites the date of event requiring filing as 06/30/2025 and contains signatures dated 08/14/2025.

Eventide is reported with sole voting and sole dispositive power over 1,356,186 shares, while Kuruvilla and John are reported with shared voting and shared dispositive power over the same 1,356,186 shares. Item 5 explicitly states this is an ownership of 5 percent or less of a class.

The filing identifies Eventide as organized in Delaware and lists the filers' address as One International Place, Suite 4210, Boston, Massachusetts. The exhibit includes a joint filing agreement executed August 14, 2025, and Item 10 contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Insights

Financial Analyst

TL;DR: Routine institutional Schedule 13G/A showing Eventide holds 1,356,186 CLDX shares (2.0%), with no declared intent to influence control.

This filing discloses a modest, passive stake: 1,356,186 shares equal to 2.0% of Celldex's common stock. Eventide is shown with sole voting and dispositive authority, while two named individuals are listed with shared powers under a joint filing arrangement. Because the stake is below 5% and the filing includes Item 10 certifications that holdings are in the ordinary course of business, this disclosure is procedural and unlikely to signal an imminent change in corporate control or strategy.

Corporate Governance Expert

TL;DR: Joint Schedule 13G/A and explicit disclaimers indicate passive investment status; the filing appears to satisfy disclosure requirements.

The document includes a signed joint filing agreement and Item 10 certification disclaiming plans to influence control, consistent with a passive investor posture. The filing classifies Eventide as an investment adviser (IA) and the individuals with codes shown in the form, and it records the procedural facts required for Schedule 13G/A. From a governance standpoint, this is a standard disclosure that increases transparency about institutional ownership but does not, by itself, create governance or control implications.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Celldex Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001

(Title of Class of Securities)

15117B202

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 15117B202

1

Names of Reporting Persons

Eventide Asset Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,356,186.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,356,186.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,356,186.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 15117B202

1

Names of Reporting Persons

Finny Kuruvilla, M.D. Ph. D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,356,186.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,356,186.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,356,186.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 15117B202

1

Names of Reporting Persons

Robin C. John

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,356,186.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,356,186.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,356,186.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Celldex Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: Perryville III Building, 53 Frontage Road, Suite 220, Hampton, New Jersey 08827
Item 2.
(a)	Name of person filing: (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")
(b)	Address or principal business office or, if none, residence: Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110
(c)	Citizenship: Eventide: Delaware Kuruvilla: United States John: United States
(d)	Title of class of securities: Common Stock, par value $0.001
(e)	CUSIP No.: 15117B202
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Eventide: 1,356,186 (ii) Kuruvilla: 1,356,186 (iii) John: 1,356,186
(b)	Percent of class: (i) Eventide: 2.0% (ii) Kuruvilla: 2.0% (iii) John: 2.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Eventide: 1,356,186 (2) Kuruvilla: 0 (3) John: 0
	(ii) Shared power to vote or to direct the vote: (1) Eventide: 0 (2) Kuruvilla: 1,356,186 (3) John: 1,356,186
	(iii) Sole power to dispose or to direct the disposition of: (1) Eventide: 1,356,186 (2) Kuruvilla: 0 (3) John: 0
	(iv) Shared power to dispose or to direct the disposition of: (1) Eventide: 0 (2) Kuruvilla: 1,356,186 (3) John: 1,356,186
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eventide Asset Management, LLC

Signature:	/s/ Peter J. Luiso
Name/Title:	Peter J. Luiso, General Counsel
Date:	08/14/2025

Finny Kuruvilla, M.D. Ph. D.

Signature:	/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:	Finny Kuruvilla, M.D., Ph. D.
Date:	08/14/2025

Robin C. John

Signature:	/s/ Robin C. John
Name/Title:	Robin C. John
Date:	08/14/2025

Exhibit Information

EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them; NOW, THEREFORE, the parties hereto agree as follows: Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them. Eventide Asset Management, LLC Date: August 14, 2025 By: /s/ Peter J. Luiso Name: Peter J. Luiso Title: General Counsel Date: August 14, 2025 Finny Kuruvilla, M.D., Ph. D. By: /s/ Finny Kuruvilla, M.D., Ph. D. Name: Finny Kuruvilla, M.D., Ph. D. Date: August 14, 2025 Robin C. John By: /s/ Robin C. John Name: Robin C. John

FAQ

How many Celldex (CLDX) shares does Eventide Asset Management report owning?

Eventide reports beneficial ownership of 1,356,186 shares of Celldex common stock.

What percentage of CLDX does the reported stake represent?

The aggregate amount reported represents 2.0% of the class.

What voting and dispositive powers are reported for Eventide on this filing?

The filing shows Eventide with sole voting power and sole dispositive power over 1,356,186 shares.

When is the date of event that required this filing and when was the form signed?

The date of event requiring filing is 06/30/2025, and the signatures are dated 08/14/2025.

Does the filing state the shares were acquired to influence control of Celldex?

No. Item 10 contains a certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control.